Biocartis Group NV provided financial guidance for the fiscal year 2023. Building on the strong performance of 2022, the company expects to take a next significant step towards operating profitability, with: product related revenues of between EUR 55 million and EUR 60 million, reflecting growth of 25%-35% when excluding sales of SARS-CoV-2 tests that are expected to further decrease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.36M | |
+73.43% | 12.41B | |
-16.51% | 8.14B | |
+16.03% | 7.2B | |
+4.95% | 5.93B | |
+13.07% | 5.43B | |
+36.46% | 4.89B | |
-19.24% | 4.09B | |
-34.06% | 2.49B | |
+1.73% | 2.04B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group Nv Provides Financial Guidance for the Fiscal Year 2023